Effect of urate-lowering therapy on all-cause and cardiovascular mortality in hyperuricemic patients without gout: A case-matched cohort study

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Chen, Jiunn Horng ^a,b   Lan, Joung Liang ^a,b   Cheng, Chi Fung ^c   Liang, Wen Miin ^c   Lin, Hsiao Yi ^d,e   Tsay, Gregory J ^a,b   Yeh, Wen Ting ^f   Pan, Wen Harn ^f,g  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; TRIACYLGLYCEROL; ANTIGOUT AGENT;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CASE CONTROL STUDY; CAUSE OF DEATH; CHEMOTHERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; GOUT; HIGH RISK POPULATION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; TAIWANESE; TREATMENT DURATION; URATE LOWERING THERAPY; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; MORTALITY; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

ADULT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 84956893320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145193     Document Type: Article

References (41)

1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811-21 doi: 10.1056/NEJMra0800885
2. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442-7
3. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131:7-13
4. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283:2404-10
5. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: A Chinese cohort study. Arthritis Rheum 2009; 61:225-32 doi: 10.1002/art.24164
6. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis 2005; 183:147-55
7. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60:981-3
8. Wen CP, David Cheng TY, Chan HT, Tsai MK, Chung WS, Tsai SP, et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis 2010; 56:273-88 doi: 10.1053/j.ajkd.2010.01.024
9. Chen JH, Wen CP, Wu SB, Lan JL, Tsai MK, Tai YP, et al. Attenuating the mortality risk of high serum uric acid: The role of physical activity underused. Ann Rheum Dis 2015; 74:2034-42 doi: 10.1136/annrheumdis-2014-205312
10. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009; 48:804-6
11. Dubreuil M, Zhu Y, Zhang Y, Seeger JD, Lu N, Rho YH, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2014; 74:1368-72 doi: 10.1136/annrheumdis-2014-205269
12. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008; 300:924-32 doi: 10.1001/jama.300.8. 924
13. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41:1183-90
14. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38:1101-6
15. Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med 2008; 148:258-67
16. Lu TH, Sun SM, Huang SM, Lin JJ. Mind your manners: quality of manner of death certification among medical examiners and coroners in Taiwan. Am J Forensic Med Pathol 2006; 27:352-4
17. Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, et al. Effect of Urate-Lowering Therapy on the Risk of Cardiovascular Disease and All-Cause Mortality in Gout Patients: A Case-Matched Cohort Study. J Rheumatol 2015; 42:1694-701 doi: 10.3899/jrheum.141542
18. Chen JH, Yeh WT, Chuang SY, Wu YY, Pan WH. Gender-specific risk factors for incident gout: A prospective cohort study. Clin Rheumatol 2012; 31:239-45 doi: 10.1007/s10067-011-1802-6
19. Taiwan Rheumatology Association. Taiwan guideline for the management of gout and hyperuricemia. Formasan Journal of Rheumatology. 2013; 27:1-26.
20. Yamanaka H. Essence of the Revised Guideline for the Management of Hyperuricemia and Gout. JMAJ. 2012; 55:324-29
21. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation 2007; 115:2340-3
22. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-To-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf 2012; 21 Suppl 2:69-80 doi: 10.1002/pds.3263
23. Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr 2011; 20:301-8
24. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21:1157-62 doi: 10.1038/ajh.2008.245
25. Krzystek-Korpacka M, Patryn E, Kustrzeba-Wojcicka I, Chrzanowska J, Gamian A, Noczynska A. The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. Clin Chem Lab Med 2011; 49:915-21 doi: 10.1515/CCLM.2011.130
26. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003; 42:321-5
27. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62:572-5
28. Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: A population-based matched-cohort study. PLoS One 2014; 9:e99102 doi: 10.1371/journal.pone.0099102
29. Taiwan Drug Relief Foundation (TDRF) for Drug Hazard. Case analysis of the reported compensation due to adverse drug effect and medical hazard in Taiwan 2011 (Chinese). Drug Safety Newsletter 2012; 37:20-28. Available: http://www.tdrf.org.tw/ch/03-message/mes-03-list.asp.
30. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U.S.A. 2005; 102:4134-9
31. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B 5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19:704-9 doi: 10.1097/FPC. 0b013e328330a3b8
32. Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009; 68:892-7 doi: 10. 1136/ard.2008.091462
33. Wagayama H, Shiraki K, Sugimoto K, Fujikawa K, Shimizu A, Takase K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 2000; 32:874
34. Hiramitsu S, Ishiguro Y, Matsuyama H, Yamada K, Kato K, Noba M, et al. Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. Clin Exp Hypertens 2014; 36:433-40 doi: 10.3109/10641963. 2013.846358
35. Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction among patients with gout: A nationwide population-based study. Rheumatology (Oxford) 2013; 52:111-7
36. Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008; 295:F1134-41 doi: 10.1152/ajprenal.00104.2008
37. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005; 67:1739-42
38. So A, Ives A, Joosten LA, Busso N. Targeting inflammasomes in rheumatic diseases. Nat Rev Rheumatol 2013; 9:391-9 doi: 10.1038/nrrheum.2013.61
39. Akdemir H, Asik Z, Pasaoglu H, Karakucuk I, Oktem IS, Koc RK. The effect of allopurinol on focal cerebral ischaemia: An experimental study in rabbits. Neurosurg Rev 2001; 24:131-5
40. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with uratelowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11:R46 doi: 10.1186/ar2659
41. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64:1431-46